Literature DB >> 11499324

Hypothalamic-pituitary suppression with oral contraceptive pills does not improve outcome in poor responder patients undergoing in vitro fertilization-embryo transfer cycles.

P Kovacs1, P E Barg, B R Witt.   

Abstract

PURPOSE: To evaluate and compare the use of OCP with GnRHa for hypothalamic-pituitary suppression in poor responder IVF patients.
METHODS: Retrospective analysis of IVF-ET cycles of poor responders. Hypothalamic-pituitary suppression with OCP (Group I, n = 29) or GnRHa (Group II, n = 52), followed by stimulation with gonadotropin, oocyte retrieval, and embryo transfer. Baseline characteristics and cycle outcomes were compared.
RESULTS: 73 women underwent 81 cycles from 1/1/1999 to 1/1/2000. Baseline characteristics were similar. 31/81 (38%) cycles were cancelled (Group I, 14/29 (48%) vs. Group II, 17/52 (33%), NS). Cycle outcomes including amount of gonadotropin, number of eggs retrieved, number of embryos transferred, and embryo quality were similar. Patients in Group I required fewer days of stimulation to reach oocyte retrieval. Pregnancy outcomes were similar in the two groups.
CONCLUSION: Our retrospective analysis revealed no improvement in IVF cycle outcomes in poor responders who received OCPs to achieve hypothalamic-pituitary suppression instead of GnRHa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499324      PMCID: PMC3455826          DOI: 10.1023/a:1016626607387

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  17 in total

1.  Ovarian response in superovulated cycles after suppression with oral contraceptive steroids.

Authors:  K A Burry; L H Greenberg; P E Patton
Journal:  Am J Obstet Gynecol       Date:  1991-06       Impact factor: 8.661

2.  Gonadotropin suppression with oral contraceptives before in vitro fertilization.

Authors:  Y Gonen; W Jacobson; R F Casper
Journal:  Fertil Steril       Date:  1990-02       Impact factor: 7.329

3.  High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients.

Authors:  V C Karande; G S Jones; L L Veeck; S J Muasher
Journal:  Fertil Steril       Date:  1990-03       Impact factor: 7.329

4.  The use of oral contraceptives to regulate oocyte retrieval.

Authors:  P E Patton; K A Burry; D P Wolf; A A Kiessling; M J Craemer
Journal:  Fertil Steril       Date:  1988-04       Impact factor: 7.329

Review 5.  Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques.

Authors:  E S Surrey; W B Schoolcraft
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

Review 6.  The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering.

Authors:  Z Shoham; M Schacter; E Loumaye; A Weissman; M MacNamee; V Insler
Journal:  Fertil Steril       Date:  1995-08       Impact factor: 7.329

7.  Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.

Authors:  M M Biljan; N G Mahutte; N Dean; R Hemmings; F Bissonnette; S L Tan
Journal:  Fertil Steril       Date:  1998-12       Impact factor: 7.329

8.  Comparison of growth hormone responses to growth hormone-releasing factor and clonidine in women with normal or poor ovarian response to gonadotropin stimulation.

Authors:  J Salat-Baroux; D Rotten; S Alvarez; J M Antoine
Journal:  Fertil Steril       Date:  1993-11       Impact factor: 7.329

9.  Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives.

Authors:  C A Benadiva; Z Ben-Rafael; L Blasco; R Tureck; L Mastroianni; G L Flickinger
Journal:  Fertil Steril       Date:  1988-09       Impact factor: 7.329

10.  Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.

Authors:  R G Brzyski; S J Muasher; K Droesch; S Simonetti; G S Jones; Z Rosenwaks
Journal:  Fertil Steril       Date:  1988-12       Impact factor: 7.329

View more
  6 in total

1.  Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield.

Authors:  Joseph M Letourneau; Hakan Cakmak; Molly Quinn; Nikita Sinha; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-07-01       Impact factor: 3.412

2.  Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients.

Authors:  Candan Iltemir Duvan; Bulent Berker; Nilgun Ozturk Turhan; Hakan Satiroglu
Journal:  J Assist Reprod Genet       Date:  2008-02-06       Impact factor: 3.412

3.  Pretreatment of normal responders in fresh in vitro fertilization cycles: A comparison of transdermal estradiol and oral contraceptive pills.

Authors:  Nigel Pereira; Allison C Petrini; Zhen N Zhou; Jovana P Lekovich; Isaac Kligman; Zev Rosenwaks
Journal:  Clin Exp Reprod Med       Date:  2016-12-26

4.  Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study.

Authors:  David H Barad; Ann Kim; Hala Kubba; Andrea Weghofer; Norbert Gleicher
Journal:  Reprod Biol Endocrinol       Date:  2013-04-04       Impact factor: 5.211

5.  Lifetime Prevalence of Abortion and Risk Factors in Women: Evidence from a Cohort Study.

Authors:  Mehdi Moradinazar; Farid Najafi; Zeinab Moradi Nazar; Behrooz Hamzeh; Yahya Pasdar; Ebrahim Shakiba
Journal:  J Pregnancy       Date:  2020-04-27

6.  Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT.

Authors:  Ensieh Shahrokh Tehrani Nejad; Fatemeh Bakhtiari Ghaleh; Bita Eslami; Fedyeh Haghollahi; Maryam Bagheri; Masoumeh Masoumi
Journal:  Int J Reprod Biomed       Date:  2018-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.